Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook

Drugmaker Eli Lilly and Co. (LLY) reported Thursday that net income for the first quarter increased about 40 percent to $1.90 billion or $2.10 per share from $1.36 billion or $1.49 per share in the year-ago quarter.

Excluding items, adjusted earnings for the quarter were $2.62 per share, compared to $1.61 per share in the prior-year quarter.

On average, seven analysts polled by Thomson Reuters expected the company to report earnings of $2.14 per share for the quarter. Analysts' estimates typically exclude special items.

World-wide revenue for the quarter grew 15 percent to $7.81 billion from $6.81 billion in the same quarter last year. Wall Street expected revenues of $6.91 billion for the quarter.

The increase in revenue reflects volume growth of 20 percent. Excluding revenue from COVID-19 antibodies and Alimta, revenue grew only 10 percent.

Products including Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Emgality, Retevmo, Cyramza and Tyvyt contributed 13 percentage points of revenue growth and represented 61 percent of total revenue.

Looking ahead to fiscal 2022, Eli Lilly now projects earnings in the range of $7.30 to $7.45 per share and adjusted in the range of $8.15 to $8.30 per share on revenues between $28.8 billion and $29.3 billion.

Previously, the company expected earnings in the range of $8.00 to $8.15 per share and adjusted in the range of $8.50 to $8.65 per share on revenues between $27.8 billion and $28.3 billion.

The Street is currently looking for earnings of $8.19 per share on revenues of $26.80 billion for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula.
Follow RTT